Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$4.83
-0.8%		$4.19
$1.21
▼
$3.81
$119.29M0.68261,100 shs293,367 shs
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$4.87
+0.2%		$4.89
$3.71
▼
$7.75
$114.25M0.6189,038 shs70,848 shs
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
$6.48
$6.48
$2.11
▼
$8.74
$28.12M0.6612,055 shsN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.65
-4.3%		$1.29
$0.16
▼
$3.39
$96.17M0.8213.72 million shs11.40 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
+2.31%+3.40%+28.50%+13.26%+195.15%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-2.21%+4.07%+6.81%+1.04%-20.98%
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
0.00%0.00%0.00%0.00%0.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-2.00%-23.91%-52.37%+118.23%-71.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$4.83
-0.8%		$4.19
$1.21
▼
$3.81
$119.29M0.68261,100 shs293,367 shs
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$4.87
+0.2%		$4.89
$3.71
▼
$7.75
$114.25M0.6189,038 shs70,848 shs
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
$6.48
$6.48
$2.11
▼
$8.74
$28.12M0.6612,055 shsN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.65
-4.3%		$1.29
$0.16
▼
$3.39
$96.17M0.8213.72 million shs11.40 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
+2.31%+3.40%+28.50%+13.26%+195.15%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-2.21%+4.07%+6.81%+1.04%-20.98%
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
0.00%0.00%0.00%0.00%0.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-2.00%-23.91%-52.37%+118.23%-71.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.00
N/AN/AN/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
2.71
Moderate Buy$15.33214.85% Upside
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
0.00
N/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.14
Hold$4.65618.48% Upside

Current Analyst Ratings Breakdown

Latest FRLN, OTLK, COYA, and AADI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
8/12/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/12/2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$14.00
7/28/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/27/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$1.60
7/27/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$4.00
7/17/2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/12/2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$14.00
6/11/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$6.00 ➝ $10.00
6/5/2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$25.07M4.76N/AN/A$4.29 per share1.13
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$7.95M14.37N/AN/A$1.84 per share2.65
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/AN/AN/AN/A$12.07 per shareN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$1.16M-82.65N/AN/A($0.07) per share-9.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$21.23M-$1.07N/AN/AN/A-270.22%-52.05%-46.34%N/A
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
-$88.97M-$5.59N/AN/AN/AN/A-150.46%-97.01%N/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$62.42M-$0.77N/AN/AN/AN/AN/A-254.82%N/A

Latest FRLN, OTLK, COYA, and AADI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q3 2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.08-$0.09-$0.01-$0.15$0.97 million$0.01 million
8/11/2026Q2 2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$0.3457-$0.28+$0.0657-$0.28$0.13 million$0.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/AN/AN/AN/AN/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
N/AN/AN/AN/AN/A
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/A
4.89
4.54
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
N/A
13.40
13.40
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/A
1.95
N/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.81
0.45

Institutional Ownership

CompanyInstitutional Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
52.08%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
39.75%
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
46.26%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%

Insider Ownership

CompanyInsider Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
37.30%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
6.10%
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
1.90%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
4024.70 million15.49 millionNo Data
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
623.46 million22.03 millionNot Optionable
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
1524.34 million4.26 millionNot Optionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
20148.59 million145.91 millionOptionable

Recent News About These Companies

Analysts Issue Forecasts for Oncobiologics FY2026 Earnings
August 21 at 7:57 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analysts-issue-forecasts-for-oncobiologics-fy2026-earnings-2026-08-21/
Brookline Capital Markets Comments on Oncobiologics Q1 Earnings
August 20 at 7:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/brookline-capital-markets-comments-on-oncobiologics-q1-earnings-2026-08-20/
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
August 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975675/otlk-q3-earnings-call-maps-lytenava-u-s-launch-and-sales-ramp?cid=cs-stocknewsapi-ft-analyst_blog_plus|earnings_call_takeaways-2975675
Short Interest in Oncobiologics, Inc. (NASDAQ:OTLK) Grows By 78.0%
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-oncobiologics-inc-nasdaqotlk-grows-by-780-2026-08-17/
Oncobiologics' (OTLK) "Buy" Rating Reiterated at BTIG Research
August 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30965452
Ghiath Sukhtian Purchases 2,525,252 Shares of Oncobiologics (NASDAQ:OTLK) Stock
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30964803
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
August 15, 2026  |  defenseworld.netD
Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Acquires $2,499,999.48 in Stock
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-otlk-insider-buying-and-selling-2026-08-15/
Oncobiologics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Hold" by Analysts
August 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30962013
Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Brokerages
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-inc-nasdaqotlk-given-average-rating-of-hold-by-brokerages-2026-08-15/
Oncobiologics (NASDAQ:OTLK) Downgraded by Wall Street Zen to Sell
August 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961505
Oncobiologics (NASDAQ:OTLK) Downgraded to "Sell" Rating by Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-downgraded-to-sell-rating-by-wall-street-zen-2026-08-15/
Oncobiologics (NASDAQ:OTLK) Director Ghiath Sukhtian Buys 2,525,252 Shares of Stock
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-director-ghiath-sukhtian-buys-2525252-shares-of-stock-2026-08-14/
Oncobiologics (NASDAQ:OTLK) Releases Earnings Results
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-releases-earnings-results-2026-08-14/
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936801-outlook-therapeutics-inc-otlk-q3-2026-earnings-call-transcript
Oncobiologics' (OTLK) Buy Rating Reaffirmed at BTIG Research
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-otlk-buy-rating-reaffirmed-at-btig-research-2026-08-14/
Oncobiologics Q3 Earnings Call Highlights
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-q3-earnings-call-highlights-2026-08-14/
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2974790/outlook-therapeutics-inc-otlk-reports-q3-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2974790
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345250/0/en/outlook-therapeutics-reports-third-quarter-fiscal-year-2026-financial-results-and-provides-business-update-highlighting-fda-approval-of-lytenava.html
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
August 14, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61200760/outlook-therapeutics-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts?utm_source=snapi
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344189/0/en/outlook-therapeutics-announces-pricing-of-55-0-million-public-offering-of-common-stock-and-warrants.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aadi Bioscience stock logo

Aadi Bioscience NASDAQ:AADI

$4.83 -0.04 (-0.82%)
As of 08/20/2026

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Coya Therapeutics stock logo

Coya Therapeutics NASDAQ:COYA

$4.87 +0.01 (+0.21%)
As of 04:00 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Freeline Therapeutics stock logo

Freeline Therapeutics NASDAQ:FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$0.65 -0.03 (-4.30%)
As of 04:00 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas